Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2011, vol. 20, nr 6, November-December, p. 737–743

Publication type: original article

Language: English

Immunohistochemical Analysis of Microvessel Density in Serous Ovarian Cancers

Analiza unaczynienia nowotworów surowiczych jajnika na podstawie immunohistochemicznej oceny gęstości naczyniowej w surowiczym raku jajnika

Radosław Blok1,, Julia Bar2,, Michał Jeleń2,, Łukasz Jagielski1,, Marian Gryboś1,

1 Ist Department of Gynaecology and Obstetrics, Wroclaw Medical University, Poland

2 Division of Pathomorphology and Clinical Cytology, Wroclaw Medical University, Poland

Abstract

Background. Angiogenesis is an essential process involved in the normal growth and differentiation of cells. Excessive angiogenesis is also a crucial event in the progression of cancer because better oxygen and nutrition substances supply increases of tumor growth. Microvessel density (MVD) is believed to be a good prognostic indicator in ovarian neoplasms because by using this method the authors can estimate the velocity of neovascularization.
Objectives. The aim of the study was to evaluate the expression of MVD in serous ovarian cancers in relation to the clinicopathological parameters of tumors.
Material and Methods. The material consisted of 41 cases of serous ovarian cancer. For clinical examinations the authors chose only patients who underwent a primary surgical operation. The control group for CD34 levels were 15 patients with benign serous adenomas. The microscopic (×200) evaluation of blood vessels in paraffin samples were done by showing the reaction of the endothelial CD34 antigen with DAKO serum (Monoclonal Mouse Anti Human CD34 class 1 – N 1574 LSAB).
Results. Immunohistochemical data revealed that the mean value of MVD was significantly higher in serous ovarian carcinomas than benign serous adenomas of the ovary (P = 0.0002). Whereas the differences between MVD expression and tumor grade were on a statistical borderline (p = 0.07) there were no statistically significant correlations between FIGO, levels of Ca125 after 3 and 6 courses of chemotherapy, and time of patient survival.
Conclusion. The results revealed that the expression of the CD34 antigen characterizes biological features of serous ovarian carcinomas. The levels of CA125 antigen in serum blood positively correlate with microvessel density and the clinical stage of the tumor.

Streszczenie

Wprowadzenie. Angiogeneza jest zasadniczym procesem zaangażowanym we wzrost oraz różnicowanie komórek i tkanek. Nadmierna angiogeneza jest również istotnym czynnikiem w procesie progresji nowotworu, która zależy od zaopatrzenia w tlen i substancje odżywcze. Ocena gęstości naczyniowej (MVD) może być uznana za prognostyk aktywnego wzrostu nowotworu, ponieważ za jej pomocą jest możliwa ocena nowotworzenia naczyń w tkankach nowotworowych.
Cel pracy. Ocena ekspresji MVD w rakach surowiczych jajnika w odniesieniu do wskaźników klinicznych i histopatologicznych.
Materiał i metody. Materiał badawczy obejmował 41 przypadków raka surowiczego jajnika. Do badań włączono jedynie pacjentki, u których pierwszym etapem leczenia był zabieg chirurgiczny i które nie miały obciążonego wywiadu onkologicznego. Grupę kontrolną stanowiło 15 przypadków gruczolaka surowiczego jajnika. Przeprowadzono mikroskopową analizę naczyń (×200) w preparatach uzyskanych z bloczków parafinowych. Ekspresję antygenu CD34 uzyskano, posługując się surowicą monoklonalną (Monoclonal Mouse Anti Human CD34 class 1 – N 1574 LSAB) firmy DAKO.
Wyniki. Immunohistochemiczne dane ujawniły, że średnia wartość MVD była znacząco większa w surowiczych rakach jajnika niż w łagodnych gruczolakach surowiczych jajnika (P = 0,0002). Poziomy ekspresji MVD w zależności od stopnia zróżnicowania komórkowego (Grading) były na granicy istotności statystycznej (P = 0,07), ale nie znaleziono korelacji między FIGO, stężeniem CA125 po 3 i 6 kursach chemioterapii i czasem przeżycia pacjentek.
Wnioski. Własne wyniki pokazują, że ekspresja antygenu CD 34 charakteryzuje właściwości biologiczne surowiczych raków jajnika. Stężenie antygenu CA125 w surowicy krwi koreluje dodatnio z gęstością naczyniową (MVD) i stopniem zaawansowania guza.

Key words

serous ovarian carcinoma, microvessel density, immunohistochemistry

Słowa kluczowe

raki surowicze jajnika, gęstość naczyniowa, immunohistochemia

References (22)

  1. Raica M, Cimpean AM, Ribatti D: Angiogenesis in pre-malignant conditions. Eur J Cancer 2009, 45, 1924–1934.
  2. Nagy VM, Buiga R, Brie I, Todor N, Tudoran O, Ordeanu C, Virag P, Tarta O, Rus M, Balacescu O: Expression of VEGF, VEGFR, EGFR, COX-2 and MVD in cervical carcinoma, in relation with the response to radiochemotherapy. Rom J Morphol Embryol 2011, 52, 53–59.
  3. Czekierdowski A, Czekierdowska S, Czuba B, Cnota W, Sodowski K, Kotarski J, Zwirska-Korczała K: Microvessel density assessment in benign and malignant endometrial changes. J Physiol Pharmacol 2008, 59(4), 45–51.
  4. Civin C, Strauss L, Brovall C, Fackler M, Schwartz, Shaper J: Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J. Immunol 1984, 133, 157–165.
  5. Imdahl A, Bognar G, Schulte-Mönting J, Schöffel U, Farthmann EH, Ihling C: Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 2002, 21, 657–663.
  6. Rubatt JM, Darcy KM, Hutson A, Bean SM, Havrilesky LJ, Grace LA, Berchuck A, Secord AA: Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. Gynecol Oncol 2009, 112, 469–474.
  7. Raspollini MR, Amunni G, Villanucci A, Baroni G, Boddi V, Rossi Degl’innocenti D, Tadei G: Microvessel density in ovarian carcinoma: computer image analysis in patients with shorter and longer survival. J Gynecol Cancer 2005, 15, 844–849.
  8. Schlingemann RO, Rietveld FJ, de Waal RM, Bradley NJ, Skene AI, Davies AJ, Greaves MF, Denekamp J, Ruiter DJ: Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 1990, 62, 690–696.
  9. Zhang Y, Tang H, Cai J, Zhang T, Guo J, Feng D, Wang Z: Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Lett 2011, 303, 47–55.
  10. Raspollini MR, Amunni G, Villanucci A, Baroni G, Boddi V, Tadei G: Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 2004, 14, 815–823.
  11. Guset G, Costi S, Lazar E, Dema A, Cornianu M, Vernic C, Paiusan L: Expression of vascular endothelial growth factor (VEGF) and assessment of microvascular density with CD34 as prognostic markers for endometrial carcinoma. Rom J Morphol Embryol 2010, 51, 677–682.
  12. Rudlowski C, Pickart AK, Fuhljahn C, Friepoertner T, Schlehe B, Biesterfeld S, Schroeder W: Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer 2006, 16, 183–189.
  13. Rossochacka-Rostalska B, Gisterek IJ, Suder E, Szelachowska JK, Matkowski RA, Lacko A, Kornafel JA: Prognostic significance of microvessel density in ovarian cancer. Wiad Lek 2007, 60, 129–137.
  14. Sharma SG, Aggarwal N, Gupta SD, Singh MK, Gupta R, Dinda AK: Angiogenesis in renal cell carcinoma: correlation of microvessel density and microvessel area with other prognostic factors. Int Urol Nephrol 2011, 43, 125–129.
  15. Amis J, Coulter-Smith S, Crow C, Maclean A, Perrett C: Microvessel quantification in benign and malignant ovarian tumors. Int J Gynecol Cancer 2005, 15, 58–65.
  16. Wang Z, Wang H, Lin M: Study on tumor angiogenesis in epithelial ovarian carcinoma J Tongji Med Univ 2000, 2, 172–174.
  17. Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, Sugisaki Y: Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000, 83, 196–203.
  18. Hata K, Dhar DK, Kanasaki H, Nakayama K, Fujiwaki R, Katabuchi H, Okamura H, Nagasue N, Miyazaki K: Serum endostatin levels in patients with epithelial ovarian cancer. Anticancer Res 2003, 23(2C), 1907–1912.
  19. Karavasilis V, Malamau-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Pavlidis N: Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma. Int J Gynecol Cancer 2006, 16(S1), 241–246.
  20. Sonmezer M, Gungor M, Ensari A, Ortac F: Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor β and vascular endothelial growth factor. Int J Gynecol Cancer 2004, 14, 82–88.
  21. Ogawa S, Kaku T, Kobayashi H: Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett 2002, 176, 111–118.
  22. Van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn HW, Dobler-Girdziunaite D, Dombi VH, Fink D, Giai M, McGing P, Harlozinska A, Kainz C, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R: Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000, 79, 444–450.